Influenza Vaccine Market Size, By Type (Quadrivalent, Trivalent), By Product (Vaxigrip/Fluzone HD/Fluzone, Afluria/Fluvirin/Fluad/Flucelvax/Aggripal, Fluarix/FluLaval, FluMist/Fluenz) - Global Industry Trends, Shares, Competitive Analysis and Segment Fore

Report - ID225173 | 01 August, 2018 | Life Sciences | 110 pages | Report Type (Global) | Publisher Name - Excelsior Research

As of 2017, the Influenza Vaccine market size was valued at USD 4.52 billion and is projected to grow at a CAGR of 12.0%. As the world moves towards an aging population, people’s susceptibility to influenza increases, raising demand for flu vaccines. Also improving healthcare systems, growing flu awareness and high birth rates in developing countries will fuel demand for existing and new influenza vaccines from 2017. The influenza vaccination industry thus holds great potential for progress and high sales.
Influenza vaccine market is expected to flourish rapidly in the near future. The key factor attributing to the market growth is the need for development of new version of influenza vaccine owing to the frequently changing influenza virus. Moreover, escalating demand of pediatrics influenza vaccines as well as high demand from emerging markets is also expected to fuel market growth during the forecast period.

The influenza vaccines market is majorly dominated by only 4 major pharmaceutical companies dominating the industry: Sanofi Pasteur, Seqirus, GSK and AstraZeneca. Sanofi held the largest share in the market with its bestselling influenza vaccine, Vaxigrip/Fluzone HD/Fluzone. It accounted for maximum share in 2017 and is anticipated to maintain its dominance throughout the forecast period. In influenza vaccine market by type segmentation quadrivalent vaccine accounted the major market share in 2017

Segments covered in the report
• Global Influenza Vaccine Market by Type (USD Million, 2016-2025) 
o Quadrivalent
o Trivalent

• Global Influenza Vaccine Market By Product (USD Million, 2016-2025) 
o Vaxigrip/Fluzone HD/Fluzone
o Afluria/Fluvirin/Fluad/Flucelvax/Aggripal
o Fluarix/FluLaval
o FluMist/Fluenz
o Others 

• Global Influenza Vaccine Market by Region (USD Million, 2016-2025) 
o US
o Germany
o UK
o France
o Italy
o Spain
o China
o India
o Japan
o Brazil
o Russia 
o RoW
1. Market Introduction
1.1 Introduction
1.2 Scope of Study
1.2.1 Research Objective
1.3 Currency & Pricing
1.4 Limitations
1.5 Assumptions
2. Executive Summary
2.1 Global Influenza Vaccine Market Projection, 2018 – 2025
2.2 Global Influenza Vaccine Market Growth, By Regions
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.4.1 Bottom-up Approach
3.4.2 Top-down Approach
3.4.3 Market Breakdown and Data Triangulation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 PEST Analysis
4.3.1 Political
4.3.2 Economical
4.3.3 Social
4.3.4 Technological
4.4 Porters Five Forces Analysis
4.5 SWOT Analysis
4.5.1 Strengths 
4.5.2 Weaknesses
4.5.3 Opportunities 
4.5.4 Threats 
5. Global Influenza Vaccine Market, By Product
5.1 Product Overview
5.2 Vaxigrip/Fluzone HD/Fluzone
5.3 Afluria/Fluvirin/Fluad/Flucelvax/Aggripal
5.4 Fluarix/FluLaval
5.5 FluMist/Fluenz
5.6 Others
6. Global Influenza Vaccine Market, By Type
6.1 Type Overview
6.2 Quadrivalent
6.3 Trivalent 
7. Global Influenza Vaccine Market, By Region
7.1 Regional Overview
7.2 U.S.
7.3 Germany 
7.4 UK
7.5 France
7.6 Italy
7.7 Spain
7.8 Japan
7.9 China
7.10 India
7.11 Brazil
7.12 Russia
8. Company Profiles
8.1 Sanofi Pasteur Inc.
8.1.1 Company/Business Overview
8.1.2 Financial Overview
8.1.3 Product Benchmarking
8.1.4 Product Pipeline
8.1.5 Key Developments
8.2 GlaxoSmithKline
8.2.1 Company/Business Overview
8.2.2 Financial Overview
8.2.3 Product Benchmarking
8.2.4 Product Pipeline
8.2.5 Key Developments
8.3 Exactech
8.3.1 Company/ Business Overview
8.3.2 Financial Overview
8.3.3 Product Benchmarking
8.3.4 Key Developments
8.4 Seqirus Corporation
8.4.1 Company/ Business Overview
8.4.2 Financial Overview
8.4.3 Product Benchmarking
8.4.4 Product Pipeline
8.4.5 Key Development
8.5 AstraZeneca
8.5.1 Company/ Business Overview
8.5.2 Financial Overview
8.5.3 Product Benchmarking
8.5.4 Key Development
8.6 Serum Institute of India Pvt. Ltd.
8.6.1 Company/ Business Overview
8.6.2 Product Benchmarking
8.7 Abbott 
8.7.1 Company/ Business Overview
8.7.2 Financial Overview
8.7.3 Product Benchmarking
8.8 Pfizer Ltd
8.8.1 Company/ Business Overview
8.8.2 Financial Overview
8.8.3 Product Benchmarking
8.9 Bio Farma
8.9.1 Company/ Business Overview
8.9.2 Product Benchmarking
8.10 Hualan Biological Engineering Inc.
8.10.1 Company/ Business Overview
8.10.2 Product Benchmarking
8.10.3 Key Developments
9. Conclusion
Leave a Message